Anmeldung erfolgt in Kürze...
Details werden geladen...
New Publication Demonstrates TLX250-Px (Zircaix®) Potential in Diagnosing Kidney Cancers Beyond ccRCC | The Manila Times
MELBOURNE, Australia and INDIANAPOLIS, May 05, 2026 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, 'Telix”) today announces the publication of a new independent analysis of Phase 3 ZIRCON trial data in European Urology1, demonstrating that TLX250-Px (Zircaix®2, 89Zr-girentuximab) PET/CT3 imaging may be highly predictive of renal malignancy across all subtypes, not limited to clear cell renal cell carcinoma (ccRCC).
Ähnliche Seiten
FDA Accepts NDA for TLX101-Px (Pixclara®) | The Manila Times
https://www.manilatimes.net/2026/04/10/tmt-newswire/pr-newswire/fda-accepts-nda-for-tlx101-px-pixclara/2317732TLX101-Px (Pixlumi®) MAA Accepted in Europe | The Manila Times
https://www.manilatimes.net/2026/05/01/tmt-newswire/pr-newswire/tlx101-px-pixlumi-maa-accepted-in-europe/2333525Telix Submits European Marketing Authorization Application for TLX101-Px for Brain Cancer Imaging | The Manila Times
https://www.manilatimes.net/2026/02/18/tmt-newswire/pr-newswire/telix-submits-european-marketing-authorization-application-for-tlx101-px-for-brain-cancer-imaging/2279964New data demonstrates the unique scalability of Evaxion’s AI-Immunology™ platform in glioblastoma | The Manila Times
https://www.manilatimes.net/2026/04/18/tmt-newswire/globenewswire/new-data-demonstrates-the-unique-scalability-of-evaxions-ai-immunology-platform-in-glioblastoma/2323029Novartis IgAN data in New England Journal of Medicine show Fabhalta® slowed kidney function decline by 49.3% | The Manila Times
https://www.manilatimes.net/2026/03/29/tmt-newswire/globenewswire/novartis-igan-data-in-new-england-journal-of-medicine-show-fabhalta-slowed-kidney-function-decline-by-493/2309947